| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-122SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-80766 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-77461SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-89104-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24755SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-76454SS | |||
| Azide and BSA Free | NBP2-80767 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-77462SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-44496 | |||
| BSA Free | NBP2-52887-25ul | |||
![<b>Genetic Strategies Validation. </b>Reduction of HIF-2alpha levels leads to protection in UV-triggered apoptosis, but not for apoptosis caused by glucose and serum starvation in 786-O cells. Parental 786-O or those either stably expressing wild-type VHLp19 or stably infected with a control vector (pSuperRetro) or a pool of two HIF-2alpha shRNAs vectors [21] were grown to confluence and lysed. Cell alpha-tubulin.](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-Knockdown-Validated-NB100-122-img0033.jpg)
![Western Blot: Rabbit Polyclonal HIF-2 alpha/EPAS1 Antibody [NB100-122] - Analysis of HIF-2 alpha/EPAS1 antibody on mouse liver nuclear extracts. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-122_rabbit-polyclonal-hif-2-alpha-epas1-antibody-western-blot-222024141448..jpg)
![Immunocytochemistry/ Immunofluorescence: HIF-2 alpha/EPAS1 Antibody - BSA Free [NB100-122] - Muscle repair following eccentric contraction–induced injury is concomitant with dynamic alterations of HIF2A & HIF1A expression in SCs.(A–C) Representative images of EDL myofibers from injured muscles at various time points (n >50 myofibers from 3 mice/group/time point) & stained for Pax7, DAPI, & EdU (A), HIF2A (B), or HIF1A (C). Scale bars: 20 μm. Arrowheads indicate SCs. (D) Number of Pax7+ SCs per myofiber at various time points. (E) Percentage of EdU+ SCs at various time points. (F) Percentage of HIF2A+ SCs at various time points. (G) Percentage of HIF1A+ SCs at various time points. Data represent the mean ± SEM. Image collected & cropped by CiteAb from the following publication (//www.jci.org/articles/view/96208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-122_rabbit-polyclonal-hif-2-alpha-epas1-antibody-31020241535648.jpg)
![Immunocytochemistry/ Immunofluorescence: HIF-2 alpha/EPAS1 Antibody - BSA Free [NB100-122] - Genetic ablation of HIF2A in QSCs leads to transient activation, proliferation, & differentiation of SCs.(B) Representative images of myofibers from SC-HIF2AKO mice & control littermates (n >50 myofibers from 5 mice/group; 10 dpr). Immunofluorescence of Pax7 (red), HIF2A (green), MyoD (purple), & DAPI (blue) staining revealed HIF2A–MyoD+ & HIF2A+MyoD– SCs (arrowheads) in SC-HIF2AKO & control mice, respectively. Scale bar: 10 μm. Image collected & cropped by CiteAb from following publication (//www.jci.org/articles/view/96208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-122_rabbit-polyclonal-hif-2-alpha-epas1-antibody-3102024153569.jpg)
![Immunocytochemistry/ Immunofluorescence: HIF-2 alpha/EPAS1 Antibody - BSA Free [NB100-122] - EpEX & EpCAM activate a STAT3-HIF2 alpha signal for EpEX/EpCAM-mediated iPSC formation.(A) iPSCs were infected with two different EpCAM shRNAs (two clones, #1 & #2). The protein expressions of EpCAM & HIF2 alpha were detected by Western blotting. (B) MEFs were stimulated by EpEX (1 μg/mL) at the indicated times. Nuclear-translocation was detected with a specific antibody against HIF2 alpha (n = 3). (C) Immunofluorescence staining was performed to detect subcellular localization of HIF2 alpha . Nuclei were stained with DAPI. Scale bar: 10 μm. (D) MEFs were treated with STAT3 inhibitor (WP1066, 10 μM), & then stimulated with EpEX for 30 min. The nuclear-translocation of HIF2 alpha was detected by Western blotting with anti-HIF2 alpha antibody (n = 3). (E) iPSC morphology was observed at day 20 after induction. Reprogramming of Oct4-GFP MEFs was induced by transfection of OSKM, OE + EpEX, & KE + EpEX with or without STAT3 inhibitor WP1066, or HIF2 alpha shRNA (n = 3). Scale bar: 50 μm. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/srep41852), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-122_rabbit-polyclonal-hif-2-alpha-epas1-antibody-310202415532070.jpg)
![Gel Super Shift Assays: HIF-2 alpha/EPAS1 Antibody - BSA Free [NB100-122] - Manipulation of DNA methylation at HRE sequences alters HIF binding. (A) The Hypoxia Response Element (HRE) contains a CpG site that can be methylated which prevents HIF1 & HIF2 binding in vitro. EMSA of in vitro–translated HIF1 & HIF2 binding to 32P-labelled unmethylated & methylated HRE probes. Competition with 250X molar excess of unlabelled/unmethylated HRE probe (lanes 3, 7,12, 16) or unlabelled control HRE-free probe (lanes 4, 8, 13, 17). HIF1 & HIF2 complexes bound to unmethylated HRE or methylated HRE supershifted with anti-HIF1 alpha (lanes 9 & 18) & anti-HIF2 alpha (lanes 5 & 14). (B) RCC4-VHL cells were grown in normoxia (NT) or treated with 25 µM decitabine (5aza) or grown in hypoxia (1%) for 48 hrs & with the addition of 25 µM decitabine (1% + 5aza). QPCR was performed using primers specific  to VEGF, uPAR, TGF alpha , GUS, U1AsnRNP1. Samples were normalised to relative expression of the housekeeping gene, ACTIN. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-21524-5), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-122_rabbit-polyclonal-hif-2-alpha-epas1-antibody-310202415532046.jpg)
![Immunocytochemistry/ Immunofluorescence: HIF-2 alpha/EPAS1 Antibody - BSA Free [NB100-122] - HIF-1 alpha /2 alpha expression in myeloid-specific KO mice targeting the HIF pathway. (A) Images of the colon of wild-type (WT), myeloid-specific Hif-1a KO (hMRP8 Hif-1a KO) or von Hippel Lindau (Vhl) KO (hMRP8 Vhl KO) mice, immunostained for MRP8 (green) & the DNA-binding regions of Hif-1a mRNA (red). Mice were fed with 5% DSS for 4 days prior to immunostaining analyses. Note that there were no MRP8-positive cells that were positive for Hif-1a mRNA in hMRP8 Hif-1a KO (middle column) mice, but we observed many cells that were double positive for MRP8 & Hif-1a mRNA in hMRP8 Vhl KO mice (right column). (B) Images of the colon of hMRP8 Vhl KO mice fed with 5% DSS as in A, immunostained for MRP8 (green) & HIF-1 alpha (red, upper row) or HIF-2 alpha (red, bottom row). DAPI-stained nuclei are shown in blue. White boxes in A & B indicate the regions magnified in the lower or right images, respectively. Yellow arrowheads in A & B indicate cells positive for both markers. Scale bars: 100 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29967068), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-122_rabbit-polyclonal-hif-2-alpha-epas1-antibody-31020241612668.jpg)
![Immunocytochemistry/ Immunofluorescence: HIF-2 alpha/EPAS1 Antibody - BSA Free [NB100-122] - HIF2 alpha stabilization results in exocrine cell atrophy & expansion of duct-like tubular structures. (A) Body weight (left panel), pancreas weight (middle panel) & body/pancreas weight ratio (right panel) in Pdx1-Cre;HIF2dPA & control mice at 2 & 8 weeks of age. Data are presented as mean ± SD. (B) HIF2 alpha accumulation in Pdx1-Cre;HIF2dPA analyzed by Western blot with anti-HA antibody. Two independent two-week-old control & mutant mice are shown. beta -actin protein was used for loading control. Full-length blots are presented in Supplementary Fig. 2. (D) Immunofluorescence analysis of HIF2 alpha in two-week-old control pancreata. Endogenous HIF2 alpha expression is observed in islets (marked by an white asterisk) but not in exocrine tissue. (D) Robust HIF2 alpha accumulation in the pancreas of two-week-old Pdx1-Cre;HIF2dPA mice. Hematoxylin/Eosin-stained pancreatic sections from P0 (E,F), two- (I,J) & eight-week-old (M,N) Pdx1-Cre;HIF2dPA & control mice. Inset in N shows an area with adipose tissue in Pdx1-Cre;HIF2dPA pancreata. Immunofluorescence of amylase & KRT19 shows no differences between Pdx1-Cre;HIF2dPA & control mice at P0 (G,H). Duct-like tubular structures & loss of amylase immunoreactivity in two- (K,L) & eight-week-old (O,P) Pdx1-Cre;HIF2dPA mice compared to control mice. Note areas with normal acini in 8-week-old Pdx1-Cre;HIF2dPA mice (white asterisk in O). Insets in (H,L & P) show higher magnification pictures. DAPI staining is shown in blue in (C,D,G,H,K,L,O & P). Scale bars = 50 µm for (C,D); 100 µm for (E–P). ***P 50 myofibers from n = 3 mice) showing that nmGFP+ QSCs were pimonidazole+. Scale bars: 50 μm & 10 μm (insets). Inset images show that pimonidazole signals were relatively enriched in the cytoplasm of QSCs. Arrowheads indicate a QSC; asterisks indicate a myonucleus. (B) Percentage of pimonidazole+ QSCs. (C) Timeline of in vivo CCI-103F labeling in C57BL/6 mice & representative images of uninjured/resting EDL myofibers (n >50 myofibers from 3 mice) showing that nmGFP+ QSCs were CCI-103F+. Arrowheads indicate a QSC; asterisks indicate a myonucleus. Scale bar: 20 μm. (D) Percentage of CCI-103F+ QSCs. (E & F) Representative images of uninjured/resting EDL myofibers from C57BL/6 mice (n >50 myofibers from 6 mice/group) showing that most QSCs were HIF2A+, but HIF1A–. Scale bars: 10 μm. (G) Percentage of HIF1A+ & HIF2A+ QSCs. Data represent the mean ± SEM. Image collected & cropped by CiteAb from the following publication (//www.jci.org/articles/view/96208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-122_rabbit-polyclonal-hif-2-alpha-epas1-antibody-310202415541931.jpg)
![Simple Western: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Lane view shows a specific band for HIF-2 alpha in 0.5 mg/mL of Hypoxic HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-ep190b-Simple-Western-NB100-132-img0009.jpg "<b>Biological Strategies Validation. </b>Simple Western: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Lane view shows a specific band for HIF-2 alpha in 0.5 mg/mL of Hypoxic HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![<b>Biological Strategies Validation. </b>Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Analysis of HIF-2 alpha stabilization over time in 791T cells following exposure to hypoxia. Image using the HRP form of this antibody (NB100-132H). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23785417/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-ep190b-Western-Blot-NB100-132-img0017.jpg)
![Immunohistochemistry-Paraffin: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Analysis of HIF-2 in human cardiac myocytes using HIF-2 alpha/EPAS1 Antibody (ep190b).](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-ep190b-Immunohistochemistry-Paraffin-NB100-132-img0018.jpg)
![Flow Cytometry: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - HIF-2 alpha antibody was tested at 1:400 in HepG2 cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-ep190b-Flow-Cytometry-NB100-132-img0006.jpg)
![Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Mouse aortic endothelial cells treated (1%) or not treated (20.9%) in hypoxia for 3 hrs. Cells where also transfected with a specific siRNA against (siHIF-2) or a control siRNA (-). Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-ep190b-Western-Blot-NB100-132-img0024.jpg)
![Immunohistochemistry-Paraffin: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Renal tubule specific models of Vhl deletion. Histological images of representative renal sections from 12 month old control, Pax8-CreERT2/Vhldelta/delta and Slc22a6-CreERT2/Vhldelta/delta mice (stains and antibodies as indicated, arrowheads indicate abnormal vascularization). Scale bars, 100 um. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0148055), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-ep190b-Immunohistochemistry-Paraffin-NB100-132-img0022.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Analysis of HepG2 without Cobalt (II) Chloride (1), HepG2 with Cobalt (II) Chloride (2), HepG2 normoxic (3), HepG2 hypoxic (4), HepG2 without Cobalt (II) Chloride (5), HepG2 with Cobalt (II) Chloride (6), HepG2 normoxic (7), and HepG2 hypoxic (8) using this antibody (NB100-132) at 1 - 2 ug/mL.](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-ep190b-Western-Blot-NB100-132-img0007.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - [HRP] [NB100-132H] - Analysis of HIF-2 alpha stabilization over time in HOS cells following exposure to hypoxia. Image using the HRP form of this antibody (NB100-132H). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23785417/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-ep190b-Western-Blot-NB100-132-img0019.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Western blot analysis and quantification of HIF-2 alpha expression in the cortex 4.5 hours after lipopolysaccharide (LPS) administration for all LPS groups and the control group (SHAM, white bar). With the exception of the vagotomy group (VGX LPS, gray bar), no significant differences to the SHAM group were found in the LPS-treated and sham-operated (SHAM+LPS, light gray bar) or vagus nerve-stimulated groups (VGX LPS+STIM, black bar). The significant increase in the VGX LPS (gray bar) group is an indicator of a hypoxic condition; * P<0.05 compared to SHAM; n=6 rats each. Data are given as the mean+/-SEM. Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-9-183), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-ep190b-Western-Blot-NB100-132-img0020.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - 4-OOHCPA exposure induced HIF-2 alpha/EPAS1. A: Western blot analysis of HIF-2 alpha/EPAS1 protein (118KD) and actin (43KD) in limbs at 10 min, 1, 3, 6, and 24 h after treatment with 4-OOHCPA at 0.3 ug/mL (L) 1.0 ug/mL (M) or 3.0 ug/mL (H). P represents the positive control. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0051937), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-ep190b-Western-Blot-NB100-132-img0021.jpg)
![Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Analysis of HIF-2 alpha in human endometrium using. Donkey anti-mouse Alexa Fluor 488 secondary antibody was used. IHC image submitted by a verified customer review.](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-ep190b-Immunohistochemistry-NB100-132-img0016.jpg)
![<b>Biological Strategies Validation and Genetic Strategies Validation.</b>Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Functional role of HIF2A in the transcriptional regulation of amphiregulin (AREG) in human cardiac myocytes. Immunoblot for HIF1A or HIF2A from shRNA-transfected normoxic or hypoxic HCM. Beta-Actin (ACTb) served as a loading control. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29483579/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-ep190b-Knockdown-Validated-NB100-132-img0025.jpg)
![Immunohistochemistry-Paraffin: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - HIF-1 alpha & HIF-2 alpha IHC signals in hypoxic areas of transgenic mouse mammary tumours.A, C Hypoxyprobe (Hyp.pr.) allows visualisation of hypoxic tumour areas. B. Hypoxic peri-necrotic HIF-1 alpha -positive cells display nuclear staining. D. HIF-2 alpha -positive cells show cytoplasmic staining with or without appreciable nuclear staining. * necrosis. E, F. IHC staining for HIF-1 alpha on MCF-7 breast cancer cells grown under control (E) & hypoxic (F) conditions respectively. G, H. Control (G) & hypoxic (H) MCF-7 cells IHC stained for HIF-2 alpha . 20x obj. Insets show magnification of the boxed area. Size bars 50 μm. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0125771), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-132_mouse-monoclonal-hif-2-alpha-epas1-antibody-ep190b-310202415371976.jpg)
![Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - HIF-2 alpha expression in the involuting mammary gland.Inserts are enlargements of the indicated areas. Size bars: 50 μm, 40x obj was used in all micrographs. A. In the early involuting gland, the morphology resembles the lactating gland & the basement membrane is evident at this stage. B-D. As tissue remodelling proceeds during involution, the collagen layer becomes unstructured. E-H. HIF-2 alpha -positive cells were detected at all studied stages of involution. I-L. Macrophage infiltration (F4/80 positive) was first evident at the fifth day of involution (J) & increased with time (K, L). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0125771), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-132_mouse-monoclonal-hif-2-alpha-epas1-antibody-ep190b-310202415345323.jpg)
![Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Oxygen concentration-dependence of dioxygenase inhibition.A. HIF1 alpha , HIF2 alpha , & H3K9me2 abundance by western blotting in shRNA1 & shRNA2 cells incubated in 21%, 10%, or 2% oxygen for 72 h. Actin & total H3 serve as loading controls. B. HIF1 alpha , HIF2 alpha , & H3K9me2 abundance by western blotting in SDHC knockout iMEFs incubated in 21%, 10%, or 2% oxygen for 72 h. iMEFs were treated with 1 μM TAM for 7 d prior to analysis. (C-D) Rescue of succinate inhibition of JMHD & PHD inhibition using 0.25 mM octyl-alpha -ketoglutarate (octyl-alpha -KG) in SDHB knockdown HEK293 cells & SDHC knockout mouse iMEFs. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0127471), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-132_mouse-monoclonal-hif-2-alpha-epas1-antibody-ep190b-31020241533499.jpg)
![Immunohistochemistry-Paraffin: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Lactating mammary gland.Smaller panels display enlargements of the indicated areas. Size bars: 50 μm, 40x obj was used for all micrographs. A. Collagen I IHC allows visualisation of the basement membrane surrounding the dilated ducts. B. HIF-1 alpha was not detected in the epithelial cells of the lactating gland (compare with Fig 1). C. Macrophage infiltration was sparse in the lactating mammary gland as judged by F4/80 IHC. D. A subset of cuboidal luminal epithelial cells was distinctively positive for HIF-2 alpha . E. The percentage of HIF-2 alpha -positive out of total luminal epithelial cells was counted in sections from three mice. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0125771), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-132_mouse-monoclonal-hif-2-alpha-epas1-antibody-ep190b-310202415384198.jpg)
![Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Mainly CK14-positive, but not CK8-positive, mammary epithelial cells are HIF-2 alpha positive at day 14 post weaning.Left panels 20x & right 40x objective. Size bars 50 μm. a, A, b & B. Double IHC for HIF-2 alpha (green) & CK8 (a, A) & CK14 (b, B), respectively (red), reveal that few (if any) CK8-positive luminal cells are HIF-2 alpha positive. Numerous CK14-expressing cells, which include basal & stem/progenitor cells, were positive for HIF-2 alpha . c, C. F4/80 IHC was performed on an adjacent tissue section detect macrophages. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0125771), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-132_mouse-monoclonal-hif-2-alpha-epas1-antibody-ep190b-31020241535676.jpg)
![Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Renal tubule specific models of Vhl deletion.(A) PCR analysis of recombination at the Vhl locus in the kidneys of mice with combinations of Pax8-CreERT2, Slc22a6-CreERT2 & the Vhl floxed (fl) & wild-type (+) alleles. The positions of the bands representing the Vhl floxed, wild type (Wt) & recombined ( delta ) alleles are indicated. (B) Histological images of representative renal sections from 12 month old control, Pax8-CreERT2/Vhl delta / delta & Slc22a6-CreERT2/Vhl delta / delta mice (stains & antibodies as indicated, arrowheads indicate abnormal vascularisation). Scale bars, 100μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26866916), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-132_mouse-monoclonal-hif-2-alpha-epas1-antibody-ep190b-31020241539741.jpg)
![Immunohistochemistry-Paraffin: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - HIF1 alpha & H3K9me2 accumulation & 5-hydroxy-methyl-2’-deoxycytidine (5hmdC) depletion in PGL specimens compared to controls.Normal ganglia 1 (NG1), normal ganglia 2 (NG2) & IDH-mutant (IDH). Sporadic PGL (Spo. PGL). A. HIF1 alpha staining. B. HIF2 alpha staining. C. H3K9me2 staining. Arrows indicate H3K9me2 staining in nuclei of neurons or chief cells. D. 5hmdC staining. Arrows indicate 5hmdC staining in the nuclei of neurons & chief cells. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0127471), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-132_mouse-monoclonal-hif-2-alpha-epas1-antibody-ep190b-310202415345316.jpg)
![Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Localization of HIF2A immunoreactivity in limbs.HIF-2A reactivity was detected in control limbs at 1 & 3 h in the apical ectodermal ridge, interdigital area (I.R.) & developing cartilaginous anlagen (Digits). 4-OOHCPA exposure increased HIF2A immunoreactivity in the apical ectodermal ridge & interdigital regions (I.R.) at 3 h. No differences were observed between control & drug-treated limbs after 6 h or 24 h of culture. Four separate replicates were done. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0051937), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-132_mouse-monoclonal-hif-2-alpha-epas1-antibody-ep190b-310202415304236.jpg)
![Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Hypoxic repression of ER-alpha is dependent on HIF-1 alpha . a Representative western blots of HIF-1 alpha , HIF-2 alpha & beta -actin protein in ten ER-positive cell lines grown at normoxia or hypoxia (1% O2, 24 h). b qPCR analysis of HIF1A mRNA levels in MCF7, BT474, T47D & ZR75B transfected with shScramble or shHIF1A. Relative HIF1A mRNA levels normalized to TBP. (Change in HIF1A levels: *p < 0.0001 MCF7, *p = 0.012 BT474, *p < 0.0001 T47D, *p = 0.0046 ZR75B). c Representative western blots of HIF-1 alpha , ER-alpha & beta -actin protein from MCF7, BT474, T47D & ZR75B with either shScramble or shHIF1A at normoxia & hypoxia (1% O2, 24 h). beta -actin is used as a loading control. d Representative western blot of HIF-1 alpha , ER-alpha & beta -actin protein from MCF7, BT474, T47D & ZR75B with or without the transfection of stabilized HIF-1 alpha (HIF-1 alpha ODD) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28320353), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-132_mouse-monoclonal-hif-2-alpha-epas1-antibody-ep190b-3102024165744.jpg)
![Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - HIF-1 alpha & HIF-2 alpha expression in the virgin mammary gland.A. Virgin mammary glands (30 & 70 days old) showed no conspicuous basal membrane, as visualised by collagen IV IHC (a, b). There was also no detectable expression of HIF-2 alpha in the epithelial cells (c, d). Macrophages (F4/80 positive) were few. In panel c, a single HIF-2 alpha -positive cell was detected, & the adjacent F4/80 IHC section (e) suggested that this cell is a macrophage. B. Expression of HIF-1 alpha in mammary epithelium in the 70-day-old virgin mouse. Top panel, orientation slide with haematoxylin (HTX) staining, 20x obj. *lymph node. Panels b, d, f. Cross-section of a developing duct close to the invading tip at a stage where the lumen is not yet evacuated, 40x obj. Panels c, e, g. Cross-section of a less mature part of a duct, 40x obj. CK14-expressing cells (marker of basal mammary epithelial cells) can be seen in more than one cell layer (panels b & c, arrow-head). At this stage, the lumen is evacuated, but there is still more than one layer of epithelial cells. HIF-1 alpha IHC on the adjacent sections (panels d, e) showing nuclear expression in non-basal epithelial cells (highlighted by red arrows). Basal (CK14 positive) epithelial cells did not express HIF-1 alpha (black arrows). Mammary epithelial expression of HIF-2 alpha was not detected at these developmental stages. Size bars: 50 μm. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0125771), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-132_mouse-monoclonal-hif-2-alpha-epas1-antibody-ep190b-310202415532017.jpg)
![Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - HIF2 alpha inhibitor 76 suppressed CoCl2-induced immature phenotypic characteristics of BCSCs(A) The inhibitory effect of small molecule HIF2 alpha inhibitor 76 for 24h (10 μM for 4T1 cells; 25 μM for Hs578T cells) on CoCl2-induced expression of HIF2 alpha was assessed in both 4T1 & Hs578T cells by western blot analysis. (B) HIF2 alpha inhibitor 76 inhibited primary (with HIF2 alpha inhibitor 76 daily treatment) & second sphere formation (without additional HIF2 alpha inhibitor 76 treatment) in both 4T1 & Hs578T cells. The sizes of spheres greater than 100 μm were enumerated, with a representative image of a tumor-sphere shown. The data represents an average of three independent experiments. (C) Treatment of 4T1 & Hs578T cells with HIF2 alpha inhibitor 76 for 24 h led to a decrease in the percentage of CD44+/CD24−-positive cells as a proportion of total cancer cells. (D) 4T1 & Hs578T cells treated with CoCl2 (100 μM) for 24h & HIF2 alpha inhibitor 76 for 24h (10 μM for 4T1 cells; 25 μM for Hs578T cells) either alone or together were evaluated for the expression levels of stem cell markers c-Myc, Klf4, Oct4, & Nanog by Real-time PCR. Abbreviations: TSFE, Tumor sphere-forming efficiency. beta -actin was used as the internal control. The results represent the mean ± SD from three independent experiments. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.9846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-132_mouse-monoclonal-hif-2-alpha-epas1-antibody-ep190b-310202415525281.jpg)
![Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Phd2 deletion leads to activation of the Akt–mTOR pathway. a RPPA analysis of tumors with homozygous deletion of Phd2. Tumor tissues from Tyr::CreER; BRafV600E; Phd2−/− or Tyr::CreER; BRafV600E mice were processed & analyzed by RPPA assays. The analyses identified proteins that were significantly changed in mouse melanomas compared to nevi. b Activation of Akt–mTOR pathway after phd2 deletion. Tumor tissues were processed & western blots showed stabilization of HIF-1 alpha & HIF-2 alpha proteins after Phd2 depletion. Increased phosphorylation of Akt, 4EBP1 & S6K was observed in tumors from Tyr::CreER; BRafV600E; Phd2−/− compared with those of Tyr::CreER; BRafV600E mice. c Re-expression of Phd2 inhibits the Akt–mTOR pathway. A BRafV600E; Phd2−/− mouse melanoma cell line was established from melanomas in Tyr::CreER; BRafCA; Phd2lox/lox mice. Phd2 was ectopically reintroduced in these tumor cells. Western blot analysis showed that degradation of HIF-1 alpha & HIF-2 alpha proteins with decreased expression of VEGFR2 decreased phosphorylation of Akt, 4EBP1 & S6K. d Pharmacological inhibition (FM19G11) of HIF pathway in BRafV600E; Phd2−/− melanoma cells. A similar but more pronounced inhibition of the Akt–mTOR pathway was observed using the HIF inhibitor. beta -Actin was used as a loading control. Results are representative of three independent experiments Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30575721), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-132_mouse-monoclonal-hif-2-alpha-epas1-antibody-ep190b-3102024161269.jpg)
![Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - BAY 87-2243 inhibits hypoxia-inducible factor (HIF-1 alpha ) & HIF-2 alpha protein accumulation in hypoxic H460 cells H460 under hypoxia but has no effect on HIF-1 alpha protein levels induced by hypoxia mimetics & has no effect on prolyl hydroxylase 2 (PHD2) activity. (A, B) H460 cells were cultured for 16Â h under normoxia or hypoxia (1% pO2) in the absence or presence of various concentrations of BAY 87-2243. HIF-1 alpha (A) & HIF-2 alpha (B) protein levels were assessed by Western Blot in whole cell extracts. beta -actin was used as a loading control. (C) H460 cells were cultured for 16Â h under normoxia with the PHDs desferrioxamine (DFO) & CoCl2 plus/minus BAY 87-2243 before the HIF1 alpha protein levels in cellular extracts were quantified by Western Blot. beta -actin was used to as a loading control. (D) Effect of BAY 87-2243 on the recombinant PHD2-mediated hydroxylation of HIF-1 alpha peptide over time was measured in a biochemical assay. Hydoxylated peptide was quantified after incubation with purified VBC complex labeled with europium using fluorescence as a readout. The known PHD inhibitor N-oxalylglycine served as a positive control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24403227), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-132_mouse-monoclonal-hif-2-alpha-epas1-antibody-ep190b-31020241555221.jpg)
![Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Cytosol-restricted Acss2 is enzymatically active.(A) Acetylation of ectopic HA-tagged HIF-2 alpha detected by immunoblotting (IB) with anti-HA or anti- acetylated lysine antibodies following immunoprecipitation (IP) with anti-HA antibody in stably transformed HT1080 cells with knockdown of endogenous Acss2 & rescue with ectopic wild-type (WT) or cytosol-restricted mutant (CYT) Acss2 without or with an SV40 nuclear localization signal fused to the amino terminus. Studies were performed under hypoxia, low glucose, or acetate exposure for the indicated periods. (B) Acetate-dependent lipid synthesis measured by 14C-acetate incorporation in HT1080 stably-transformed cells producing control or Acss2 shRNA downstream of a luciferase cDNA cassette & expressing ectopic control, WT, CYT, SV40-WT, or SV40-CYT Acss2. Cells were incubated under (A) control, (B) hypoxic, or (C) low glucose conditions for 48 hr with labeling performed during the last 24 hr. Comparison of samples within a given condition was made by one-way ANOVA followed by Dunnett’s multiple comparisons test using control shRNA knockdown/control rescue as reference with decreased samples noted (*, P<0.05). All values are means with SD. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0190241), licensed under a CC0-1.0 license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-132_mouse-monoclonal-hif-2-alpha-epas1-antibody-ep190b-310202415525235.jpg)
![Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - In vitro effects of diclofenac on proliferation & MYC expression in the human melanoma cell line MelIm.The human melanoma cell line MelIm was incubated with different concentrations of diclofenac (A), aspirin (ASA, B), & NS-398 (C), respectively, & proliferation was determined after 24 h. Results represent the mean +/− standard deviation of 12 (diclofenac) & 3 (ASA, NS-398) independent experiments, respectively. (D) MelIm were incubated for 24 h with or without diclofenac. Apoptotic cells were stained with Annexin-V-FITC/ 7-AAD & analyzed by flow cytometry. Results represent the mean +/− standard deviation of 3 independent experiments. (E-G) MYC, STAT3, HIF1a & HIF2a protein expression were determined in cell lysates of MelIm incubated for 2 or 24 h with or without diclofenac (E,F) or ASA (G). The effect of diclofenac on MYC promoter activity was determined by transient transfection of a 2632-bp MYC promoter fragment (H). MelIm were transfected in 6-well-plates & diclofenac was added after 5 h. Luciferase activity was determined 24 h after transfection. Results represent the mean +/− standard deviation of 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0066987), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-132_mouse-monoclonal-hif-2-alpha-epas1-antibody-ep190b-310202415535152.jpg)
![Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Phd2 deletion leads to activation of the Akt–mTOR pathway. a RPPA analysis of tumors with homozygous deletion of Phd2. Tumor tissues from Tyr::CreER; BRafV600E; Phd2−/− or Tyr::CreER; BRafV600E mice were processed & analyzed by RPPA assays. The analyses identified proteins that were significantly changed in mouse melanomas compared to nevi. b Activation of Akt–mTOR pathway after phd2 deletion. Tumor tissues were processed & western blots showed stabilization of HIF-1 alpha & HIF-2 alpha proteins after Phd2 depletion. Increased phosphorylation of Akt, 4EBP1 & S6K was observed in tumors from Tyr::CreER; BRafV600E; Phd2−/− compared with those of Tyr::CreER; BRafV600E mice. c Re-expression of Phd2 inhibits the Akt–mTOR pathway. A BRafV600E; Phd2−/− mouse melanoma cell line was established from melanomas in Tyr::CreER; BRafCA; Phd2lox/lox mice. Phd2 was ectopically reintroduced in these tumor cells. Western blot analysis showed that degradation of HIF-1 alpha & HIF-2 alpha proteins with decreased expression of VEGFR2 decreased phosphorylation of Akt, 4EBP1 & S6K. d Pharmacological inhibition (FM19G11) of HIF pathway in BRafV600E; Phd2−/− melanoma cells. A similar but more pronounced inhibition of the Akt–mTOR pathway was observed using the HIF inhibitor. beta -Actin was used as a loading control. Results are representative of three independent experiments Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30575721), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-132_mouse-monoclonal-hif-2-alpha-epas1-antibody-ep190b-31020241555248.jpg)
![Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Phd2 deletion leads to activation of the Akt–mTOR pathway. a RPPA analysis of tumors with homozygous deletion of Phd2. Tumor tissues from Tyr::CreER; BRafV600E; Phd2−/− or Tyr::CreER; BRafV600E mice were processed & analyzed by RPPA assays. The analyses identified proteins that were significantly changed in mouse melanomas compared to nevi. b Activation of Akt–mTOR pathway after phd2 deletion. Tumor tissues were processed & western blots showed stabilization of HIF-1 alpha & HIF-2 alpha proteins after Phd2 depletion. Increased phosphorylation of Akt, 4EBP1 & S6K was observed in tumors from Tyr::CreER; BRafV600E; Phd2−/− compared with those of Tyr::CreER; BRafV600E mice. c Re-expression of Phd2 inhibits the Akt–mTOR pathway. A BRafV600E; Phd2−/− mouse melanoma cell line was established from melanomas in Tyr::CreER; BRafCA; Phd2lox/lox mice. Phd2 was ectopically reintroduced in these tumor cells. Western blot analysis showed that degradation of HIF-1 alpha & HIF-2 alpha proteins with decreased expression of VEGFR2 decreased phosphorylation of Akt, 4EBP1 & S6K. d Pharmacological inhibition (FM19G11) of HIF pathway in BRafV600E; Phd2−/− melanoma cells. A similar but more pronounced inhibition of the Akt–mTOR pathway was observed using the HIF inhibitor. beta -Actin was used as a loading control. Results are representative of three independent experiments Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30575721), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-132_mouse-monoclonal-hif-2-alpha-epas1-antibody-ep190b-310202415541965.jpg)
![Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - In-vivo lentiviral delivery of Cre-recombinase to renal tubular epithelium results in recombination of target genes.(a) Diagram of pCCIE lentiviral construct. Cre, Cre-recombinase; IRES, internal ribosome entry site; GFP, Green fluorescent protein. (b) Anti-VHL, HIF1a & GAPDH immunoblots of renal cortical protein lysates from Vhlwt/wt & Vhlfl/fl mice intrarenally injected with CCIE. Samples were collected 12 months post infection with each column representing an individual mouse. Blots were cropped to improve clarity, full-length blots are presented in Supplementary Fig. S3a. (c) Histological images of renal sections from Vhlwt/wt & Vhlfl/fl mice intrarenally injected with CCIE at 12 months post injection (stains & antibodies as indicated). Scale bars, 100 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26046460), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-132_mouse-monoclonal-hif-2-alpha-epas1-antibody-ep190b-310202415541994.jpg)
![Immunohistochemistry-Paraffin: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - HIF-1 alpha & HIF-2 alpha expression in the virgin mammary gland.A. Virgin mammary glands (30 & 70 days old) showed no conspicuous basal membrane, as visualised by collagen IV IHC (a, b). There was also no detectable expression of HIF-2 alpha in the epithelial cells (c, d). Macrophages (F4/80 positive) were few. In panel c, a single HIF-2 alpha -positive cell was detected, & the adjacent F4/80 IHC section (e) suggested that this cell is a macrophage. B. Expression of HIF-1 alpha in mammary epithelium in the 70-day-old virgin mouse. Top panel, orientation slide with haematoxylin (HTX) staining, 20x obj. *lymph node. Panels b, d, f. Cross-section of a developing duct close to the invading tip at a stage where the lumen is not yet evacuated, 40x obj. Panels c, e, g. Cross-section of a less mature part of a duct, 40x obj. CK14-expressing cells (marker of basal mammary epithelial cells) can be seen in more than one cell layer (panels b & c, arrow-head). At this stage, the lumen is evacuated, but there is still more than one layer of epithelial cells. HIF-1 alpha IHC on the adjacent sections (panels d, e) showing nuclear expression in non-basal epithelial cells (highlighted by red arrows). Basal (CK14 positive) epithelial cells did not express HIF-1 alpha (black arrows). Mammary epithelial expression of HIF-2 alpha was not detected at these developmental stages. Size bars: 50 μm. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0125771), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-132_mouse-monoclonal-hif-2-alpha-epas1-antibody-ep190b-31020241553385.jpg)
![Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - Analysis of HIF-2 alpha in human endometrium using. Donkey anti-mouse Alexa Fluor 488 secondary antibody was used. Image from verified customer review. HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132]](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-Pack-Immunohistochemistry-NB100-902HIF2-img0010.jpg "Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - Analysis of HIF-2 alpha in human endometrium using. Donkey anti-mouse Alexa Fluor 488 secondary antibody was used. Image from verified customer review. HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132]")
![<b>Biological Strategies Validation. </b>Western Blot: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - WNT11 is induced by hypoxia or hypoxic mimetics in different cell types. Immunoblot analyses of HeLa cells under normal air or hypoxia for 24 hrs. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep21520) licensed under a CC-BY license. HIF-2 alpha/EPAS1 Antibody [NB100-122]](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-Pack-Western-Blot-NB100-902HIF2-img0012.jpg)
![Simple Western: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - Lane view shows a specific band for HIF-2 alpha in 0.5 mg/ml of Hypoxic HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132]](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-Pack-Simple-Western-NB100-902HIF2-img0009.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - HIF-1alpha is the predominant transcriptional regulator of WNT11 expression during hypoxia. EMSCs isolated from the indicated mouse genotypes were infected with lentivirus expressing GFP or Cre recombinase. Non-infected cells and GFP infected cells served as controls. Immunoblot analyses of EMSCs derived from the indicated genotypes treated with 0.1 mM DMOG for 24 hrs. Attenuated WNT11 expression in Hif-1alpha KO EMSCs (lenti-Cre infected Hif-1af/f). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep21520) licensed under a CC-BY license. HIF-2 alpha/EPAS1 Antibody [NB100-122]](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-Pack-Knockout-Validated-NB100-902HIF2-img0013.jpg)
![<b>Orthogonal Strategies Validation. </b>Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - Formalin-fixed paraffin-embedded tissue sections of human placenta were probed for HIF-2 alpha/EPAS1 mRNA (ACD RNAScope Probe, catalog #410598; Fast Red chromogen, ACD catalog # 322750). Adjacent tissue section was processed for immunohistochemistry using Rabbit Polyclonal (Novus Biologicals catalog # NB100-122) at 1:100 dilution with one-hour incubation at room temperature followed by incubation with anti-rabbit IgG VisUCyte HRP Polymer Antibody (Catalog # VC003) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to trophoblastic cells. HIF-2 alpha/EPAS1 Antibody [NB100-122]](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-Pack-Immunohistochemistry-NB100-902HIF2-img0014.jpg)
![Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - Normal ganglia 1 (NG1), normal ganglia 2 (NG2) and IDH-mutant (IDH). Sporadic PGL (Spo. PGL). HIF2 alpha staining. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0127471) licensed under a CC-BY license. HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132]](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-Pack-Immunohistochemistry-NB100-902HIF2-img0011.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody - BSA Free [NBP1-77461] - RUNX2/CBFA1 Antibody [NBP1-77461] - Vascularization of mineralized cell-laden collagen and interaction with prostate cancer cells. HUVECs formed endothelial networks that were supported by SMA-expressing hMSCs (scale bar: 50m) and were also positive for CD31 (scale bar: 400m). The remainder of hMSCs expressed RUNX2 as a marker for osteogenic differentiation (scale bar: 50m). Rapid fabrication of vascularized and innervated cell-laden bone models with biomimetic intrafibrillar collagen mineralization. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31388010/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Immunohistochemistry-Paraffin-NBP1-77461-img0009.jpg "Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody - BSA Free [NBP1-77461] - RUNX2/CBFA1 Antibody [NBP1-77461] - Vascularization of mineralized cell-laden collagen and interaction with prostate cancer cells. HUVECs formed endothelial networks that were supported by SMA-expressing hMSCs (scale bar: 50m) and were also positive for CD31 (scale bar: 400m). The remainder of hMSCs expressed RUNX2 as a marker for osteogenic differentiation (scale bar: 50m). Rapid fabrication of vascularized and innervated cell-laden bone models with biomimetic intrafibrillar collagen mineralization. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31388010/) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: RUNX2/CBFA1 Antibody [NBP1-77461] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with RUNX2/CBFA1 Antibody (NBP1-77461) at 1 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-77461-img0010.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody - BSA Free [NBP1-77461] - RUNX2/CBFA1 Antibody [NBP1-77461] - Characterization of TLC cultured in chondrogenic pellets. Gene expression of TLC cultured four weeks in chondrogenic pellets or in cell monolayer in control medium: levels of expression of osteoblast markers (1), chondrocyte markers (2) and tenocyte markers (3) (N = 3) assessed by qPCR.* =0.05. Rotator Cuff Tenocytes Differentiate into Hypertrophic Chondrocyte-Like Cells to Produce Calcium Deposits in an Alkaline Phosphatase-Dependent Manner. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31561454/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Immunohistochemistry-Paraffin-NBP1-77461-img0008.jpg)
![Immunohistochemistry: RUNX2/CBFA1 Antibody [NBP1-77461] - Staining of RUNX2 in mouse prostate using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Immunohistochemistry-NBP1-77461-img0006.jpg)
![Immunohistochemistry: RUNX2/CBFA1 Antibody - BSA Free [NBP1-77461] - Histological characterization of rotator cuff calcifications (N = 5). (A) Calcific deposits assessed by micro-computed tomography. (B) HE (hematoxylin & eosin) staining of decalcified samples (1 image for each patient). (C) Von Kossa staining on not decalcified samples & characterization of the fibrocartilaginous area with alcian blue staining, SOFG (Safranin O/Fast Green) staining, & immunohistochemical staining for COL2 (brown) with Gill hematoxylin counterstain. (D,E) Representative immunohistochemical staining for ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1), TNAP (tissue non-specific alkaline phosphatase), Runx2, Sox9, Col10 & CD31 (brown). TF: tendon fibers; CD: calcium deposits, FM: fibrocartilaginous metaplasia; OM: osseous metaplasia; CT: connective tissue; V: vessels. Scale bar = 200 µM. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31561454), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77461_rabbit-polyclonal-runx2-cbfa1-antibody-310202416154628.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody [NBP1-89104] - Staining in human tonsil and liver tissues . Corresponding RUNX2 RNA-seq data are presented for the same tissues.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Immunohistochemistry-Paraffin-NBP1-89104-img0015.jpg "<b>Orthogonal Strategies Validation. </b>Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody [NBP1-89104] - Staining in human tonsil and liver tissues . Corresponding RUNX2 RNA-seq data are presented for the same tissues.")
![<b>Orthogonal Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: RUNX2/CBFA1 Antibody [NBP1-89104] - Staining of human cell line U-2 OS shows localization to nucleoplasm. Antibody staining is shown in green.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-89104-img0012.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody [NBP1-89104] - Staining of human tonsil shows moderate to strong nuclear positivity in a subset lymphoid cells.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Immunohistochemistry-Paraffin-NBP1-89104-img0007.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody [NBP1-89104] - Staining of human liver shows no positivity as expected.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Immunohistochemistry-Paraffin-NBP1-89104-img0008.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody [NBP1-89104] - Staining of human rectum shows moderate to strong nuclear positivity in lymphoid cells.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Immunohistochemistry-Paraffin-NBP1-89104-img0009.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody [NBP1-89104] - Staining of human salivary gland shows moderate to strong nuclear positivity in ductal cells.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Immunohistochemistry-Paraffin-NBP1-89104-img0010.jpg)
![<b>Genetic Strategies Validation. </b>Knockdown Validated: RUNX2/CBFA1 Antibody [NBP1-89104] - Analysis in U-251MG cells transfected with control siRNA, target specific siRNA probe #1 and #2. Remaining relative intensity is presented. Loading control: Anti-GAPDH.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Knockdown-Validated-NBP1-89104-img0014.jpg)
![Western Blot: RUNX2/CBFA1 Antibody (1D8) [H00000860-M01] - Analysis of RUNX2 expression in transfected 293T cell line by RUNX2 monoclonal antibody (M01), clone 1D8.Lane 1: RUNX2 transfected lysate (Predicted MW: 60.28 KDa).Lane 2: Non-transfected lysate.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-1D8-Western-Blot-H00000860-M01-img0013.jpg "Western Blot: RUNX2/CBFA1 Antibody (1D8) [H00000860-M01] - Analysis of RUNX2 expression in transfected 293T cell line by RUNX2 monoclonal antibody (M01), clone 1D8.Lane 1: RUNX2 transfected lysate (Predicted MW: 60.28 KDa).Lane 2: Non-transfected lysate.")
![Immunocytochemistry/Immunofluorescence: RUNX2/CBFA1 Antibody (1D8) [H00000860-M01] - Analysis of monoclonal antibody to RUNX2 on U-2 OS cell . Antibody concentration 10 ug/ml.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-1D8-Immunocytochemistry-Immunofluorescence-H00000860-M01-img0008.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody (1D8) [H00000860-M01] - Analysis of monoclonal antibody to RUNX2 on formalin-fixed paraffin-embedded human placenta. Antibody concentration 3 ug/ml.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-1D8-Immunohistochemistry-Paraffin-H00000860-M01-img0010.jpg)
![Western Blot: RUNX2/CBFA1 Antibody (1D8) [H00000860-M01] - Western Blot analysis of RUNX2 expression in SJCRH30 ( Cat # L027V1 ).](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-1D8-Western-Blot-H00000860-M01-img0001.jpg)
![Western Blot: RUNX2/CBFA1 Antibody (1D8) [H00000860-M01] - Western Blot analysis of RUNX2 expression in K-562 ( Cat # L009V1 ).](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-1D8-Western-Blot-H00000860-M01-img0003.jpg)
![Western Blot: RUNX2/CBFA1 Antibody (1D8) [H00000860-M01] - RUNX2 monoclonal antibody (M01), clone 1D8. Analysis of RUNX2 expression in Jurkat.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-1D8-Western-Blot-H00000860-M01-img0012.jpg)
![Sandwich ELISA: RUNX2/CBFA1 Antibody (1D8) [H00000860-M01] - Detection limit for recombinant GST tagged RUNX2 is approximately 0.03ng/ml as a capture antibody.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-1D8-Sandwich-ELISA-H00000860-M01-img0011.jpg)
![Western Blot: RUNX2/CBFA1 Antibody [NBP2-24755] - Analysis of human RUNX2 in Saos-2 cell lysate in the 1) absence and 2) presence of immunizing peptide using RUNX2 antibody at 2 ug/mL.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Western-Blot-NBP2-24755-img0002.jpg "Western Blot: RUNX2/CBFA1 Antibody [NBP2-24755] - Analysis of human RUNX2 in Saos-2 cell lysate in the 1) absence and 2) presence of immunizing peptide using RUNX2 antibody at 2 ug/mL.")
![Western Blot: Rabbit Polyclonal RUNX2/CBFA1 Antibody [IMGENEX: IMG-5985A] [NBP2-24755] - Bone lysate homogenate from goats. SDS-PAGE with 0.3 mg of total protein from the homogenate per well. RUNX/CBFA1, NBP2-24755 was used at a dilution of 1:1000 and BMP-2, NBP1-32218 was used at a dilution of 1:1000 in TBS Tween and 5% milk powder. The protein was labeled at 70 kDa. Quantification of RUNX2 in bone graft in the tibia of intrailiac cellularized goats at different times compared with tibial autograft and untreated bone defect. Evaluation of pre-cellularized graft in the iliac crest in the treatment of bone defects in the tibia of goats. G1: cellularized graft for 4 weeks applied to the tibial bone defect, G2: cellularized graft for 6 weeks applied to the tibial bone defect, G3: cellularized graft for 8 weeks applied to the tibial bone defect, G4: tibial autograft and G5: untreated bone defect. All groups were evaluated 120 days after graft implantation. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nbp2-24755_rabbit-polyclonal-runx2-cbfa1-antibody-imgenex-img-5985a-western-blot-2952025142732..jpg)
![Western Blot: RUNX2/CBFA1 Antibody (3F5) [H00000860-M06] - Western Blot analysis of RUNX2 expression in Hela NE ( Cat # L012V1 ).](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-3F5-Western-Blot-H00000860-M06-img0001.jpg "Western Blot: RUNX2/CBFA1 Antibody (3F5) [H00000860-M06] - Western Blot analysis of RUNX2 expression in Hela NE ( Cat # L012V1 ).")
![Immunocytochemistry/Immunofluorescence: RUNX2/CBFA1 Antibody (3F5) [H00000860-M06] - Analysis of monoclonal antibody to RUNX2 on U-2 OS cell. Antibody concentration 10 ug/ml](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-3F5-Immunocytochemistry-Immunofluorescence-H00000860-M06-img0005.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody (3F5) [H00000860-M06] - Analysis of monoclonal antibody to RUNX2 on formalin-fixed paraffin-embedded human placenta. Antibody concentration 3 ug/ml](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-3F5-Immunohistochemistry-Paraffin-H00000860-M06-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: RUNX2/CBFA1 Antibody (3F5) [H00000860-M06] - Immunofluorescence of monoclonal antibody to RUNX2 on U-2 OS cell . [antibody concentration 10 ug/ml]](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-3F5-Immunocytochemistry-Immunofluorescence-H00000860-M06-img0003.jpg)
![ELISA: RUNX2/CBFA1 Antibody (3F5) [H00000860-M06] - Detection limit for recombinant GST tagged RUNX2 is approximately 0.1ng/ml as a capture antibody.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-3F5-ELISA-H00000860-M06-img0004.jpg)
![Western Blot: HIF-2 alpha/EPAS1 Antibody (2444A) [NBP2-76454] - Total protein from human U87 cells treated for 4 hours with and without 100 uM cobalt chloride (CoCl2) and under normoxic and hypoxic conditions, was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-HIF-2 alpha in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-2444A-Western-Blot-NBP2-76454-img0001.jpg "Western Blot: HIF-2 alpha/EPAS1 Antibody (2444A) [NBP2-76454] - Total protein from human U87 cells treated for 4 hours with and without 100 uM cobalt chloride (CoCl2) and under normoxic and hypoxic conditions, was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-HIF-2 alpha in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.")
![Western Blot: HIF-2 alpha/EPAS1 Antibody (2444A) [NBP2-76454] - Human MDA MB 231 cells. 50 ug cell lysate per lane. 10% SDS-PAGE. HIF-2 alpha antibody at 1:1000 in 5% milk. HRP-conjugated donkey anti-rabbit IgG polyclonal secondary antibody at 1:2000 in 5% milk. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-2444A-Western-Blot-NBP2-76454-img0003.jpg)
![Immunohistochemistry-Paraffin: HIF-2 alpha/EPAS1 Antibody (2444A) [NBP2-76454] - Analysis of an FFPE tissue section of the human renal carcinoma using 1:100 dilution of HIF-2 alpha antibody (NBP2-76454). The signal was developed using HRP-DAB method which followed counterstaining of the cells with hematoxylin. The antibody generated staining mainly in the nuclear with minor cytoplasmic staining.](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-2444A-Immunohistochemistry-Paraffin-NBP2-76454-img0002.jpg)
![Western Blot: RUNX2/CBFA1 Antibody (SD208-0) [NBP2-67777] - Analysis of RUNX2/CBFA1 on different lysates with Rabbit anti-RUNX2/CBFA1 antibody at 1/500 dilution. Lane 1: HL-60 cell lysate Lane 2: Jurkat cell lysate Lysates/proteins at 10 ug/Lane. Predicted band size: 57 kDa Observed band size: 57 kDa Exposure time: 1 minute; 10% SDS-PAGE gel. Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody at 1/500 dilution was used in 5% NFDM/TBST at room temperature for 2 hours. Goat Anti-Rabbit IgG - HRP Secondary Antibody at 1:300,000 dilution was used for 1 hour at room temperature.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-SD208-0-Western-Blot-NBP2-67777-img0005.jpg "Western Blot: RUNX2/CBFA1 Antibody (SD208-0) [NBP2-67777] - Analysis of RUNX2/CBFA1 on different lysates with Rabbit anti-RUNX2/CBFA1 antibody at 1/500 dilution. Lane 1: HL-60 cell lysate Lane 2: Jurkat cell lysate Lysates/proteins at 10 ug/Lane. Predicted band size: 57 kDa Observed band size: 57 kDa Exposure time: 1 minute; 10% SDS-PAGE gel. Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody at 1/500 dilution was used in 5% NFDM/TBST at room temperature for 2 hours. Goat Anti-Rabbit IgG - HRP Secondary Antibody at 1:300,000 dilution was used for 1 hour at room temperature.")
![Immunocytochemistry/Immunofluorescence: RUNX2/CBFA1 Antibody (SD208-0) [NBP2-67777] - Staining RUNX2 in SW480 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-SD208-0-Immunocytochemistry-Immunofluorescence-NBP2-67777-img0002.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody (SD208-0) [NBP2-67777] - Analysis of paraffin-embedded mouse bone tissue with Rabbit anti-RUNX2/CBFA1 antibody washed with ddH2O and PBS, and then probed with the primary antibody at 1/200 dilution for 1 hour at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-SD208-0-Immunohistochemistry-Paraffin-NBP2-67777-img0009.jpg)
![Western Blot: RUNX2/CBFA1 Antibody (SD208-0) [NBP2-67777] - Analysis of RUNX2 on different lysates. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody (1/500) was used in 5% BSA at room temperature for 2 hours. Goat Anti-Rabbit IgG - HRP Secondary Antibody at 1:5,000 dilution was used for 1 hour at room temperature. Positive control: Lane 1: mouse spleen tissue lysateLane 2: U937 cell lysate Lane 3: HL-60 cell lysate](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-SD208-0-Western-Blot-NBP2-67777-img0003.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody (SD208-0) [NBP2-67777] - Analysis of paraffin-embedded human tonsil tissue using anti-RUNX2 antibody. Counter stained with hematoxylin.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-SD208-0-Immunohistochemistry-Paraffin-NBP2-67777-img0001.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody (SD208-0) [NBP2-67777] - Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-RUNX2/CBFA1 antibody. The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 8.0-8.4) for 20 minutes. The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody (1/50) for 30 minutes at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-SD208-0-Immunohistochemistry-Paraffin-NBP2-67777-img0004.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody (SD208-0) [NBP2-67777] - Analysis of paraffin-embedded human tonsil tissue using anti-RUNX2/CBFA1 antibody. The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 8.0-8.4) for 20 minutes.The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody (1/50) for 30 minutes at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-SD208-0-Immunohistochemistry-Paraffin-NBP2-67777-img0006.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody (SD208-0) [NBP2-67777] - Analysis of paraffin-embedded human colon tissue with Rabbit anti-RUNX2/CBFA1 antibody washed with ddH2O and PBS, and then probed with the primary antibody at 1/500 dilution for 1 hour at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-SD208-0-Immunohistochemistry-Paraffin-NBP2-67777-img0007.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody (SD208-0) [NBP2-67777] - Analysis of paraffin-embedded human spleen tissue with Rabbit anti-RUNX2/CBFA1 antibody washed with ddH2O and PBS, and then probed with the primary antibody at 1/500 dilution for 1 hour at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-SD208-0-Immunohistochemistry-Paraffin-NBP2-67777-img0008.jpg)
![Immunohistochemistry: RUNX2/CBFA1 Antibody [NBP1-77462] - Staining of RUNX2 in mouse prostate using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Immunohistochemistry-NBP1-77462-img0005.jpg "Immunohistochemistry: RUNX2/CBFA1 Antibody [NBP1-77462] - Staining of RUNX2 in mouse prostate using DAB with hematoxylin counterstain.")
![Immunocytochemistry/Immunofluorescence: RUNX2/CBFA1 Antibody [NBP1-77462] - RUNX2 antibody was tested in HeLa cells with FITC (green). Nuclei and alpha-tubulin were counterstained with Dapi (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-77462-img0006.jpg)
![Flow Cytometry: RUNX2/CBFA1 Antibody [NBP1-77462] - An intracellular stain was performed on HeLa cells with RUNX2/CBFA1 Antibody NBP1-77462AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Flow-Cytometry-NBP1-77462-img0007.jpg)
![Western Blot: RUNX2/CBFA1 Antibody (CL0232) [NBP2-52887] - Analysis in U-251MG cells transfected with control siRNA, target specific siRNA probe #1 and #2, using Anti-RUNX2 antibody. Remaining relative intensity is presented. Loading control: Anti-PPIB.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-CL0232-Western-Blot-NBP2-52887-img0006.jpg "<b>Genetic Strategies Validation. </b>Western Blot: RUNX2/CBFA1 Antibody (CL0232) [NBP2-52887] - Analysis in U-251MG cells transfected with control siRNA, target specific siRNA probe #1 and #2, using Anti-RUNX2 antibody. Remaining relative intensity is presented. Loading control: Anti-PPIB.")
![<b>Genetic Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: RUNX2/CBFA1 Antibody (CL0232) [NBP2-52887] - Staining of RH-30 cells using the Anti-RUNX2 monoclonal antibody, showing specific staining in the nucleoplasm in green. Microtubule- and nuclear probes are visualized in red and blue, respectively (where available).](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-CL0232-Immunocytochemistry-Immunofluorescence-NBP2-52887-img0007.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody (CL0232) [NBP2-52887] - Staining of human tonsil shows nuclear immunoreactivity in a subset of lymphoid cells outside the reaction centrum.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-CL0232-Immunohistochemistry-Paraffin-NBP2-52887-img0004.jpg)
![Western Blot: RUNX2/CBFA1 Antibody (CL0232) [NBP2-52887] - Lane 1: Marker [kDa], Lane 2: Human cell line U-251 MG](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-CL0232-Western-Blot-NBP2-52887-img0005.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody (CL0232) [NBP2-52887] - Staining of human rectum shows nuclear positivty in lymphoid cells.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-CL0232-Immunohistochemistry-Paraffin-NBP2-52887-img0001.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody (CL0232) [NBP2-52887] - Staining of human small intestine shows nuclear immunoreactivity in lymphoid cells.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-CL0232-Immunohistochemistry-Paraffin-NBP2-52887-img0002.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody (CL0232) [NBP2-52887] - Staining of human testis shows absence of staining (negative control).](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-CL0232-Immunohistochemistry-Paraffin-NBP2-52887-img0003.jpg)